|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KIF20B |
Gene summary for KIF20B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KIF20B | Gene ID | 9585 |
| Gene name | kinesin family member 20B | |
| Gene Alias | CT90 | |
| Cytomap | 10q23.31 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q96Q89 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9585 | KIF20B | LZE2T | Human | Esophagus | ESCC | 4.17e-04 | 9.77e-01 | 0.082 |
| 9585 | KIF20B | LZE4T | Human | Esophagus | ESCC | 2.08e-02 | 2.19e-01 | 0.0811 |
| 9585 | KIF20B | LZE22T | Human | Esophagus | ESCC | 4.65e-03 | 3.92e-01 | 0.068 |
| 9585 | KIF20B | LZE24T | Human | Esophagus | ESCC | 3.73e-03 | 2.23e-01 | 0.0596 |
| 9585 | KIF20B | P2T-E | Human | Esophagus | ESCC | 1.02e-24 | 7.92e-01 | 0.1177 |
| 9585 | KIF20B | P4T-E | Human | Esophagus | ESCC | 1.57e-11 | 5.96e-01 | 0.1323 |
| 9585 | KIF20B | P5T-E | Human | Esophagus | ESCC | 5.68e-14 | 4.72e-01 | 0.1327 |
| 9585 | KIF20B | P8T-E | Human | Esophagus | ESCC | 5.95e-08 | 2.92e-01 | 0.0889 |
| 9585 | KIF20B | P10T-E | Human | Esophagus | ESCC | 1.37e-07 | 2.65e-01 | 0.116 |
| 9585 | KIF20B | P12T-E | Human | Esophagus | ESCC | 2.45e-09 | 2.48e-01 | 0.1122 |
| 9585 | KIF20B | P15T-E | Human | Esophagus | ESCC | 1.27e-02 | 2.18e-01 | 0.1149 |
| 9585 | KIF20B | P16T-E | Human | Esophagus | ESCC | 6.89e-09 | 3.06e-01 | 0.1153 |
| 9585 | KIF20B | P19T-E | Human | Esophagus | ESCC | 4.25e-02 | 2.91e-01 | 0.1662 |
| 9585 | KIF20B | P20T-E | Human | Esophagus | ESCC | 2.65e-05 | 3.40e-01 | 0.1124 |
| 9585 | KIF20B | P21T-E | Human | Esophagus | ESCC | 5.45e-14 | 4.89e-01 | 0.1617 |
| 9585 | KIF20B | P22T-E | Human | Esophagus | ESCC | 1.81e-02 | 1.30e-01 | 0.1236 |
| 9585 | KIF20B | P23T-E | Human | Esophagus | ESCC | 4.61e-03 | 2.26e-01 | 0.108 |
| 9585 | KIF20B | P24T-E | Human | Esophagus | ESCC | 4.40e-04 | 2.65e-01 | 0.1287 |
| 9585 | KIF20B | P26T-E | Human | Esophagus | ESCC | 2.17e-11 | 4.18e-01 | 0.1276 |
| 9585 | KIF20B | P27T-E | Human | Esophagus | ESCC | 4.31e-07 | 2.95e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007269811 | Liver | HCC | protein localization to microtubule cytoskeleton | 35/7958 | 54/18723 | 7.73e-04 | 4.65e-03 | 35 |
| GO:00606063 | Liver | HCC | tube closure | 53/7958 | 89/18723 | 8.67e-04 | 5.14e-03 | 53 |
| GO:0007088 | Liver | HCC | regulation of mitotic nuclear division | 63/7958 | 110/18723 | 1.24e-03 | 6.85e-03 | 63 |
| GO:00219154 | Liver | HCC | neural tube development | 82/7958 | 152/18723 | 2.83e-03 | 1.33e-02 | 82 |
| GO:00018384 | Liver | HCC | embryonic epithelial tube formation | 66/7958 | 121/18723 | 4.94e-03 | 2.07e-02 | 66 |
| GO:00721754 | Liver | HCC | epithelial tube formation | 70/7958 | 132/18723 | 9.29e-03 | 3.57e-02 | 70 |
| GO:00351484 | Liver | HCC | tube formation | 77/7958 | 148/18723 | 1.20e-02 | 4.39e-02 | 77 |
| GO:003238615 | Oral cavity | OSCC | regulation of intracellular transport | 218/7305 | 337/18723 | 6.91e-22 | 1.41e-19 | 218 |
| GO:01400145 | Oral cavity | OSCC | mitotic nuclear division | 191/7305 | 287/18723 | 1.99e-21 | 3.70e-19 | 191 |
| GO:003315718 | Oral cavity | OSCC | regulation of intracellular protein transport | 155/7305 | 229/18723 | 1.05e-18 | 1.28e-16 | 155 |
| GO:00073469 | Oral cavity | OSCC | regulation of mitotic cell cycle | 266/7305 | 457/18723 | 3.87e-17 | 3.41e-15 | 266 |
| GO:190495119 | Oral cavity | OSCC | positive regulation of establishment of protein localization | 196/7305 | 319/18723 | 2.89e-16 | 2.20e-14 | 196 |
| GO:005122219 | Oral cavity | OSCC | positive regulation of protein transport | 187/7305 | 303/18723 | 7.37e-16 | 5.49e-14 | 187 |
| GO:003238818 | Oral cavity | OSCC | positive regulation of intracellular transport | 134/7305 | 202/18723 | 2.82e-15 | 1.88e-13 | 134 |
| GO:009031610 | Oral cavity | OSCC | positive regulation of intracellular protein transport | 110/7305 | 160/18723 | 2.10e-14 | 1.19e-12 | 110 |
| GO:00482852 | Oral cavity | OSCC | organelle fission | 265/7305 | 488/18723 | 3.22e-12 | 1.27e-10 | 265 |
| GO:00002801 | Oral cavity | OSCC | nuclear division | 237/7305 | 439/18723 | 9.62e-11 | 2.90e-09 | 237 |
| GO:000716318 | Oral cavity | OSCC | establishment or maintenance of cell polarity | 129/7305 | 218/18723 | 1.16e-09 | 2.86e-08 | 129 |
| GO:00457879 | Oral cavity | OSCC | positive regulation of cell cycle | 173/7305 | 313/18723 | 3.28e-09 | 7.44e-08 | 173 |
| GO:00325065 | Oral cavity | OSCC | cytokinetic process | 33/7305 | 39/18723 | 5.91e-09 | 1.26e-07 | 33 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KIF20B | SNV | Missense_Mutation | c.2560N>T | p.Ser854Cys | p.S854C | Q96Q89 | protein_coding | tolerated(0.12) | possibly_damaging(0.887) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| KIF20B | SNV | Missense_Mutation | c.5099T>A | p.Ile1700Lys | p.I1700K | Q96Q89 | protein_coding | tolerated(0.05) | benign(0.01) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| KIF20B | SNV | Missense_Mutation | c.3128N>A | p.Arg1043Gln | p.R1043Q | Q96Q89 | protein_coding | tolerated(0.61) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KIF20B | SNV | Missense_Mutation | novel | c.3230N>C | p.Gln1077Pro | p.Q1077P | Q96Q89 | protein_coding | deleterious(0.01) | benign(0.278) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KIF20B | SNV | Missense_Mutation | novel | c.2411C>G | p.Ser804Cys | p.S804C | Q96Q89 | protein_coding | deleterious(0.02) | benign(0.439) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KIF20B | SNV | Missense_Mutation | novel | c.825N>G | p.Phe275Leu | p.F275L | Q96Q89 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-E9-A3X8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphane | CR |
| KIF20B | SNV | Missense_Mutation | novel | c.1783N>A | p.Leu595Ile | p.L595I | Q96Q89 | protein_coding | deleterious(0.01) | probably_damaging(0.913) | TCGA-Z7-A8R5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
| KIF20B | insertion | Nonsense_Mutation | novel | c.1385_1386insATTTTAGG | p.Tyr463PhefsTer2 | p.Y463Ffs*2 | Q96Q89 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| KIF20B | insertion | Nonsense_Mutation | novel | c.1387_1388insGAGTAAATATAAATCAGCCTTC | p.Tyr463Ter | p.Y463* | Q96Q89 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| KIF20B | insertion | Nonsense_Mutation | novel | c.4957_4958insGAGGAGGCTGAGAT | p.Ala1653GlyfsTer4 | p.A1653Gfs*4 | Q96Q89 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |